EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2017
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms EXTEND
- 09 Aug 2017 Planned End Date changed from 30 Sep 2019 to 31 Dec 2018.
- 09 Aug 2017 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2018.
- 15 Jun 2017 Planned number of patients changed from 56 to 40.